1 active not recruiting, 1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow Interleukin-3 Receptor Subunit Alpha Positive: new trials by email Literature Review of Interleukin-3 Receptor Subunit Alpha Positive trials Research Report on Interleukin-3 Receptor Subunit Alpha Positive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Anti-CD123/CD3 Monoclonal Antibody MGD006 - Acute Biphenotypic Leukemia, Acute Leukemia | Phase 2 | Withdrawn | City of Hope Medical Center | 2020-10-20 | 2020-12-17 | |
| Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm cyclophosphamide, Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes, laboratory biomarker analysis - Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia | Phase 1 | Active not recruiting | City of Hope Medical Center | 31 | 2015-12-15 | 2026-08-26 |
Blastic Plasmacytoid Dendritic Cell Neoplasm (2) · Leukemia, Biphenotypic, Acute (2) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (2) · Hematologic Neoplasms (1) · Hodgkin Disease (1) · Leukemia, Hairy Cell (1) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myeloid, Acute (1) · Mastocytosis, Systemic (1) · Neoplasm, Residual (1)
Hematologic Diseases (2) · Hemic and Lymphatic Diseases (2) · Histiocytic Disorders, Malignant (2) · Immune System Diseases (2) · Immunoproliferative Disorders (2) · Leukemia (2) · Leukemia, Lymphoid (2) · Leukemia, Myeloid (2) · Lymphatic Diseases (2) · Lymphoma (2) · Lymphoproliferative Disorders (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Pathologic Processes (2)
Cyclophosphamide (1) · fludarabine phosphate (1)
City of Hope Medical Center (2)
United States (1)
Ibrahim Aldoss, MD (1) · Lihua E. Budde (1)